ADC Therapeutics
ADCT
106 hedge funds and large institutions have $271M invested in ADC Therapeutics in 2025 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 31 increasing their positions, 22 reducing their positions, and 3 closing their positions.
667% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 3
49% more capital invested
Capital invested by funds: $182M → $271M (+$89.2M)
41% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 22
23% more funds holding
Funds holding: 86 → 106 (+20)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
8.22% less ownership
Funds ownership: 68.52% → 60.3% (-8.2%)
56% less call options, than puts
Call options by funds: $161K | Put options by funds: $364K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$4.38M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$4.18M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.5M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.15M |
| 5 |
Morgan Stanley
New York
|
+$1.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$9.44M |
| 2 |
HCM
Heights Capital Management
San Francisco,
California
|
-$7.9M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$2.64M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$2.26M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.78M |
ADCT Hedge Fund Activity: Q3 2025 in Review
106 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q3 2025, worth a combined $271M — up 49% from $182M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ADCT positions and 3 closed out — a net gain of 20 holders — while 31 added to existing stakes and 22 trimmed.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $4.38M. The largest seller was Prosight Management, cutting an estimated $9.44M.
- 106 institutional investors held ADC Therapeutics (ADCT) as of Q3 2025, up from 86 in Q2 2025.
- Funds reported $271M of ADC Therapeutics stock for Q3 2025, up 49% quarter-over-quarter.
- 23 funds opened new ADC Therapeutics positions in Q3 2025 and 3 closed out, a net change of +20 holders.
- The largest ADC Therapeutics buyer in Q3 2025 was TCG Crossover Management, an estimated $4.38M added.
- The largest ADC Therapeutics seller in Q3 2025 was Prosight Management, an estimated $9.44M sold.
Based on aggregated 13F filings for Q3 2025.